Tuesday November 24 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Gentris Corporation

Gentris Corporation is transforming global drug development with clinical pharmacogenomic solutions that can accelerate drug development and significantly reduce costs, resulting in more predictable response to drug therapy and less frequent, less severe adverse drug reactions (ADRs).
For every 5,000 drug candidates that enter pre-clinical testing, the Food and Drug Administration will approve only one. As a result, pharmaceutical organizations are under pressure to reduce costs and to address the key reasons for drug failure - ADRs, lack of efficacy and unfavorable pharmacokinetics/drug metabolism properties.

ADRs are currently the fourth leading cause of death and the fifth leading cause of illness in the United States. Gentris helps reduce this statistic with clinical pharmacogenomic testing that will identify patients that may exhibit drug intolerance earlier in the development cycle. With better characterization of patient populations, pharmacogenomics can help reduce drug failure rates by enabling drug companies to modify patients' exposure to drugs based on their drug-response genotype. This can offer the added benefit of making drugs that might otherwise not be approved or withdrawn to become available to patients with compatible pharmacogenomic profiles. Other benefits include shorter and more focused clinical trials that offer the promise of getting drugs to market faster, with higher safety profiles and at lower cost.


Company Mission
Gentris Corporation will lead the new paradigm in healthcare by enabling the administration of medication based on individual genetic variation by offering high quality pharmacogenomic laboratory testing services and diagnostic products.


Contact Details:
Morrisville
New York
27560
United States of America
Tel:919.465.0100
Fax:
Email:pgxinfo@gentris.com
WWW:

www.gentris.com/




Loading...

Recent Publications by Gentris Corporation:

Gentris corporation.
Gentris Corporation is engaged in the development and rapid...
26th November, 2002
Gentris Corporation, 215 Southport Drive, Suite 300, Morrisville, NC Pharmacogenomics. 2002 Jan;3(1):148-50.
DOI Direct Link

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 339 times since April 2007, the link to the organisation's website has been followed 53 times

Recent Search Terms used to find this page: gentris | Gentris | gentris | gentris | .

Search for more companies in Morrisville

Search for more companies in New York



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Gentris Corporation

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.